Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 153,800 shares on February 5, 2026, marking a decrease of 0.37% [1][2] - Over the past five trading days, there have been three days of net reductions by southbound funds, totaling 427,300 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 2,033,000 shares [1] Group 2 - As of now, southbound funds hold 41,678,300 shares of Spring Medical, which represents 43.79% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as the hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [2]

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 23,200 shares on February 5, indicating a consistent trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the past 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 42,900 shares [1] - Over the last 20 trading days, southbound funds have reduced their holdings for all 20 days, resulting in a cumulative net reduction of 188,000 shares [1] - Currently, southbound funds hold 5,681,300 shares of Gaoshi Medical, accounting for 3.83% of the company's total issued ordinary shares [1] Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and other services [1] - The proprietary products segment develops and produces surgical equipment, related software, intraocular lenses, and diagnostic and treatment devices for eye diseases [1]

Trading Information Summary - On February 5, 2026, Xiangsheng Medical (688358) closed at 35.6 yuan, down 0.95%, with a turnover rate of 0.85% and a trading volume of 9,475 shares, amounting to a total transaction value of 33.89 million yuan [1]. - On the same day, the net outflow of main funds was 93,300 yuan, accounting for 0.28% of the total transaction value; the net inflow of retail funds was 1.95 million yuan, accounting for 5.77% of the total transaction value; and the net outflow of individual investors was 1.86 million yuan, accounting for 5.49% of the total transaction value [1][3]. Company Announcement Summary - Xiangsheng Medical announced a cash dividend distribution for the first three quarters of 2025, with a cash dividend of 0.30 yuan per share (including tax), based on a total share capital of 112,125,613 shares, resulting in a total cash dividend distribution of 33,637,683.90 yuan [1]. - The record date for the dividend distribution is February 11, 2026, the ex-dividend date is February 12, 2026, and the cash dividend payment date is also February 12, 2026. This profit distribution does not include stock dividends or capital increases [1].

Group 1 - The core point of the article is that Weili Medical has received EU MDR certification for multiple products, allowing them to be legally sold in the EU market [1][3]. - On February 5, 2026, Weili Medical's stock closed at 14.57 yuan, with an increase of 1.25% and a trading volume of 52,200 shares, amounting to a total transaction value of 75.83 million yuan [1]. - The net capital flow on February 5 shows a net outflow of 324,100 yuan from main funds, while retail funds experienced a net outflow of 46,400 yuan [1][3]. Group 2 - The products that received EU MDR certification include urinary catheter care kits, drainage bags, puncture guides, nebulizers, and various other medical devices [1]. - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028 [1].

截至2026年2月5日收盘，春立医疗(688236)报收于23.13元，上涨0.43%，换手率0.44%，成交量1.27万 手，成交额2937.3万元。 来自交易信息汇总：2月5日主力资金净流入113.92万元，占总成交额3.88%。 来自公司公告汇总：截至2026年1月31日，春立医疗H股与A股注册资本及发行股份总数无变动， H股公众持股量符合上市规则要求。 2月5日主力资金净流入113.92万元，占总成交额3.88%；游资资金净流出33.09万元，占总成交额 1.13%；散户资金净流出80.83万元，占总成交额2.75%。 公司公告汇总H股市场公告 北京市春立正达医疗器械股份有限公司提交截至2026年1月31日的证券变动月报表。公司H股和A股的法 定/注册股本在本月无变动，H股总数为95,140,500股，A股总数为288,428,000股，总注册资本为人民币 383,568,500元。已发行股份中，H股为95,140,500股，无库存股；A股已发行股份为288,428,000股，其中 库存股1,376,851股。公司确认H股公众持股量符合上市规则要求。本月无股份增减变动，所有发行事项 均已获董事会批准并 ...

Group 1 - The stock price of Yingke Medical (300677) closed at 40.94 yuan on February 5, 2026, down by 0.46%, with a turnover rate of 1.23%, a trading volume of 57,100 shares, and a transaction amount of 233 million yuan [1] - On February 5, the net outflow of main funds was 4.5111 million yuan, while the net inflow of speculative funds was 16.974 million yuan, and the net outflow of retail funds was 12.4629 million yuan [2] Group 2 - Yingke Medical announced that it provided a joint liability guarantee of 300 million yuan for its wholly-owned subsidiary, Shandong Yingke Medical Products Co., Ltd., to apply for credit from Huaxia Bank Weifang Branch [1] - The total guarantee balance of the company and its subsidiaries reached 1,616,652.02 million yuan, accounting for 92.89% of the company's most recent audited net assets [1][2] - The guarantee matters have been approved by the board of directors, the board of supervisors, and the shareholders' meeting, with no overdue guarantees and no guarantees for entities outside the consolidated financial statements [1]

Trading Information Summary - On February 5, 2026, Zhendemedical (603301) closed at 69.95 yuan, down 0.63%, with a turnover rate of 0.35% and a trading volume of 9,325 lots, amounting to 65.14 million yuan [1] - On the same day, the net inflow of main funds was 339.93 thousand yuan, accounting for 5.22% of the total trading volume; the net inflow of speculative funds was 558.76 thousand yuan, accounting for 8.58% of the total trading volume; while retail investors experienced a net outflow of 898.69 thousand yuan, accounting for 13.8% of the total trading volume [1][2] Company Announcement Summary - Zhendemedical announced a change in the project quality reviewer for the 2025 audit, with Wang Wen taking over from Zheng Chuanxian due to work adjustments [1] - Wang Wen has been a certified public accountant since 2011 and has been providing audit services for the company since 2025, having signed or reviewed audit reports for multiple listed companies in the past three years [1] - The change in the quality reviewer will not affect the normal progress of the company's 2025 financial statement and internal control audit [1][2]

Core Viewpoint - Wanfu Biotech (300482) is focusing on strategic collaborations and technological advancements in the field of AI and gene sequencing to enhance its product offerings and market presence. Group 1: Strategic Collaborations - The company signed a strategic cooperation agreement with Tencent Health in May 2025, aiming to explore AI applications in disease detection, clinical decision support, and family health management [2] - The collaboration with Beiden Medical is seen as a key step to tap into the vast market potential in grassroots healthcare, focusing on optimizing products to meet the core needs of "accurate, fast, simple, and affordable" [4][5] Group 2: Technological Advancements - The company is exploring the integration of AI technology with gene sequencing to improve data analysis and interpretation efficiency, although specific product plans were not disclosed [2][3] - There are plans to develop more user-friendly devices suitable for grassroots healthcare settings, addressing the need for quick identification in rural health centers [4] Group 3: Market Outlook and Growth Targets - The global market for gene sequencing is projected to reach $20.2 billion by 2032, prompting the company to set mid- to long-term growth targets for its gene sequencing business [3] - The company is actively monitoring industry trends and is expected to provide updates on its core products' sales and revenue contributions in future reports [5] Group 4: Financial Insights - On February 5, 2026, Wanfu Biotech's stock closed at 20.65 yuan, down 0.91%, with a trading volume of 68,000 shares and a turnover of 140 million yuan [1] - On the same day, there was a net outflow of 3.77 million yuan from main funds, indicating a slight withdrawal of institutional investment [6]

（编辑 任世碧） 证券日报网讯 2月5日，三鑫医疗发布公告称，公司控股子公司成都威力生生物科技有限公司（简称"成 都威力生"）因生产经营需要，对《医疗器械生产许可证》的生产地址进行变更并完成了变更登记手 续，于近日取得了四川省药品监督管理局换发的《医疗器械生产许可证》。 ...

Core Viewpoint - The company received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission on February 5, 2026, regarding issues related to the recognition of revenue from foreign sales orders and internal controls [1] Group 1: Revenue Recognition Issues - The company was found to have recognized revenue from certain foreign sales orders in 2023 without the corresponding goods being actually declared for customs and subsequently returned [1] - This indicates a lack of prudence in the revenue recognition process for foreign sales orders [1] Group 2: Internal Control Deficiencies - The internal controls related to foreign sales at the company were deemed inadequate, with incomplete documentation for some foreign sales orders [1] - This highlights potential weaknesses in the company's operational processes and compliance measures [1]